A new chimeric protein represses HIV-1 LTR-mediated expression by DNA methylase

Antiviral Research

Volumn 98, Issue 3, 2013, Pages 394-400

  Martinez Colom, Alberto ^a,b   Lasarte, Sandra ^a,b   Fernández Pineda, Alejandra ^a,b   Relloso, Miguel ^a,b   Muñoz Fernández, Maria Angeles ^a,b,c  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

Author keywords

DNA methyltransferases; DNMT3b; HIV 1; IN3b chimeric protein; LTRs

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHIMERIC PROTEIN; DNA METHYLTRANSFERASE; IN3B PROTEIN; INTEGRASE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANTIVIRAL ACTIVITY; ARTICLE; CELL NUCLEUS; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LONG TERMINAL REPEAT; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DOMAIN; PROTEIN METHYLATION; TRANSCRIPTION REGULATION; VIRUS GENOME; VIRUS INHIBITION; VIRUS REPLICATION;

CATALYTIC DOMAIN; CELL NUCLEUS; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; DRUG EVALUATION, PRECLINICAL; GENE SILENCING; GENETIC VECTORS; GENOME, VIRAL; HEK293 CELLS; HIV INTEGRASE; HIV LONG TERMINAL REPEAT; HIV-1; HUMANS; POINT MUTATION; PROMOTER REGIONS, GENETIC; RECOMBINANT FUSION PROTEINS; TRANSCRIPTION, GENETIC; TRANSFECTION; VIRUS INTEGRATION; VIRUS LATENCY; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84877098366     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2013.04.007     Document Type: Article

References (41)

1. Ansel K.M., Lee D.U., Rao A. An epigenetic view of helper T cell differentiation. Nat. Immunol. 2003, 4:616-623.
2. Blazkova J., Trejbalova K., Gondois-Rey F., Halfon P., Philibert P., Guiguen A., Verdin E., Olive D., Van Lint C., Hejnar J., Hirsch I. CpG methylation controls reactivation of HIV from latency. PLoS Pathog. 2009, 5:e1000554.
3. Bogdanovic O., Veenstra G.J. DNA methylation and methyl-CpG binding proteins: developmental requirements and function. Chromosoma 2009, 118:549-565.
4. Boyes J., Bird A. Repression of genes by DNA methylation depends on CpG density and promoter strength: evidence for involvement of a methyl-CpG binding protein. EMBO J. 1992, 11:327-333.
5. Clemente M.I., Alvarez S., Serramia M.J., Turriziani O., Genebat M., Leal M., Fresno M., Munoz-Fernandez M.A. Non-steroidal anti-inflammatory drugs increase the antiretroviral activity of nucleoside reverse transcriptase inhibitors in HIV type-1-infected T-lymphocytes: role of multidrug resistance protein 4. Antivir. Ther. 2009, 14:1101-1111.
6. Chavez L., Kauder S., Verdin E. In vivo, in vitro, and in silico analysis of methylation of the HIV-1 provirus. Methods 2011, 53:47-53.
7. Chonco L., Pion M., Vacas E., Rasines B., Maly M., Serramia M.J., Lopez-Fernandez L., De la Mata J., Alvarez S., Gomez R., Munoz-Fernandez M.A. Carbosilane dendrimer nanotechnology outlines of the broad HIV blocker profile. J. Control. Release 2012, 161:949-958.
8. Chun T.W., Fauci A.S. HIV reservoirs: pathogenesis and obstacles to viral eradication and cure. AIDS 2012, 26:1261-1268.
9. Dong A., Yoder J.A., Zhang X., Zhou L., Bestor T.H., Cheng X. Structure of human DNMT2, an enigmatic DNA methyltransferase homolog that displays denaturant-resistant binding to DNA. Nucleic Acids Res. 2001, 29:439-448.
10. Fang J.Y., Mikovits J.A., Bagni R., Petrow-Sadowski C.L., Ruscetti F.W. Infection of lymphoid cells by integration-defective human immunodeficiency virus type 1 increases de novo methylation. J. Virol. 2001, 75:9753-9761.
11. Florl A.R., Lower R., Schmitz-Drager B.J., Schulz W.A. DNA methylation and expression of LINE-1 and HERV-K provirus sequences in urothelial and renal cell carcinomas. Br. J. Cancer 1999, 80:1312-1321.
12. Friedrich B., Li G., Dziuba N., Ferguson M.R. Quantitative PCR used to assess HIV-1 integration and 2-LTR circle formation in human macrophages, peripheral blood lymphocytes and a CD4+ cell line. Virol. J. 2010, 7:354.
13. Garcia-Merino I., de Las Cuevas N., Jimenez J.L., Gallego J., Gomez C., Prieto C., Serramia M.J., Lorente R., Munoz-Fernandez M.A. The Spanish HIV BioBank: a model of cooperative HIV research. Retrovirology 2009, 6:27.
14. Geeraert L., Kraus G., Pomerantz R.J. Hide-and-seek: the challenge of viral persistence in HIV-1 infection. Annu. Rev. Med. 2008, 59:487-501.
15. Gowher H., Liebert K., Hermann A., Xu G., Jeltsch A. Mechanism of stimulation of catalytic activity of Dnmt3A and Dnmt3B DNA-(cytosine-C5)-methyltransferases by Dnmt3L. J. Biol. Chem. 2005, 280:13341-13348.
16. Griffiths, D.J., 2001. Endogenous retroviruses in the human genome sequence. Genome Biol 2, REVIEWS1017.
17. Hsieh C.L. Dynamics of DNA methylation pattern. Curr. Opin. Genet. Dev. 2000, 10:224-228.
18. Huehn J., Polansky J.K., Hamann A. Epigenetic control of FOXP3 expression: the key to a stable regulatory T-cell lineage?. Nat. Rev. Immunol. 2009, 9:83-89.
19. Jordan A., Defechereux P., Verdin E. The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation. EMBO J. 2001, 20:1726-1738.
20. Kioussis D., Georgopoulos K. Epigenetic flexibility underlying lineage choices in the adaptive immune system. Science 2007, 317:620-622.
21. Laska M.J., Nissen K.K., Nexo B.A. (Some) cellular mechanisms influencing the transcription of human endogenous retrovirus, HERV-Fc1. PLoS One 2013, 8:e53895.
22. Lassen K., Han Y., Zhou Y., Siliciano J., Siliciano R.F. The multifactorial nature of HIV-1 latency. Trends Mol Med. 2004, 10:525-531.
23. Lavie L., Kitova M., Maldener E., Meese E., Mayer J. CpG methylation directly regulates transcriptional activity of the human endogenous retrovirus family HERV-K(HML-2). J. Virol. 2005, 79:876-883.
24. Lee G.R., Kim S.T., Spilianakis C.G., Fields P.E., Flavell R.A. T helper cell differentiation: regulation by cis elements and epigenetics. Immunity 2006, 24:369-379.
25. Li F., Papworth M., Minczuk M., Rohde C., Zhang Y., Ragozin S., Jeltsch A. Chimeric DNA methyltransferases target DNA methylation to specific DNA sequences and repress expression of target genes. Nucleic Acids Res. 2007, 35:100-112.
26. Liu K., Wang Y.F., Cantemir C., Muller M.T. Endogenous assays of DNA methyltransferases: evidence for differential activities of DNMT1, DNMT2, and DNMT3 in mammalian cells in vivo. Mol. Cell Biol. 2003, 23:2709-2719.
27. Mikovits J.A., Young H.A., Vertino P., Issa J.P., Pitha P.M., Turcoski-Corrales S., Taub D.D., Petrow C.L., Baylin S.B., Ruscetti F.W. Infection with human immunodeficiency virus type 1 upregulates DNA methyltransferase, resulting in de novo methylation of the gamma interferon (IFN-gamma) promoter and subsequent downregulation of IFN-gamma production. Mol. Cell Biol. 1998, 18:5166-5177.
28. Mok H.P., Lever A.M. Chromatin, gene silencing and HIV latency. Genome Biol. 2007, 8:228.
29. Navarro J., Punzon C., Jimenez J.L., Fernandez-Cruz E., Pizarro A., Fresno M., Munoz-Fernandez M.A. Inhibition of phosphodiesterase type IV suppresses human immunodeficiency virus type 1 replication and cytokine production in primary T cells: involvement of NF-kappaB and NFAT. J. Virol. 1998, 72:4712-4720.
30. Nordeen S.K., Ogden C.A., Taraseviciene L., Lieberman B.A. Extreme position dependence of a canonical hormone response element. Mol. Endocrinol. 1998, 12:891-898.
31. Okano M., Bell D.W., Haber D.A., Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 1999, 99:247-257.
32. Palacios J.A., Perez-Pinar T., Toro C., Sanz-Minguela B., Moreno V., Valencia E., Gomez-Hernando C., Rodes B. Long-term nonprogressor and elite controller patients who control viremia have a higher percentage of methylation in their HIV-1 proviral promoters than aviremic patients receiving highly active antiretroviral therapy. J. Virol. 2012, 86:13081-13084.
33. Perelson A.S., Essunger P., Cao Y., Vesanen M., Hurley A., Saksela K., Markowitz M., Ho D.D. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997, 387:188-191.
34. Rhoades K.L., Golub S.H., Economou J.S. The regulation of the human tumor necrosis factor alpha promoter region in macrophage, T cell, and B cell lines. J. Biol. Chem. 1992, 267:22102-22107.
35. Richman D.D. HIV Chemotherapy Nat. 2001, 410:995-1001.
36. Robertson K.D. DNA methylation and chromatin - unraveling the tangled web. Oncogene 2002, 21:5361-5379.
37. Steingrover R., Pogany K., Fernandez Garcia E., Jurriaans S., Brinkman K., Schuitemaker H., Miedema F., Lange J.M., Prins J.M. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy. AIDS 2008, 22:1583-1588.
38. Tripathy M.K., Abbas W., Herbein G. Epigenetic regulation of HIV-1 transcription. Epigenomics 2011, 3:487-502.
39. Wilson C.B., Rowell E., Sekimata M. Epigenetic control of T-helper-cell differentiation. Nat. Rev. Immunol. 2009, 9:91-105.
40. Yamagishi M., Ishida T., Miyake A., Cooper D.A., Kelleher A.D., Suzuki K., Watanabe T. Retroviral delivery of promoter-targeted shRNA induces long-term silencing of HIV-1 transcription. Microbes Infect. 2009, 11:500-508.
41. Yokochi T., Robertson K.D. Preferential methylation of unmethylated DNA by mammalian de novo DNA methyltransferase Dnmt3a. J. Biol. Chem. 2002, 277:11735-11745.